Slide 1: Full Year 2022 Results
Full Year 2022 Results 23 MARCH 2023
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Mondher Mahjoubi Joyson Karakunnel Yannis Morel Frédéric Lombard MD MD, MSc, FACP PhD MBA Chief Executive Officer EVP EVP SVP Chairman of the Executive Board Chief Medical Officer Head of Business Development Chief Financial Officer and Product Portfolio Strategy
Slide 4: Scientific innovation drives our strategy
Scientific innovation drives our strategy Our ambition – leverage our scientific know-how in innate immunity and antibody engineering to develop cancer Drive near-term Advance our Build a sustainable value with innovative business through drugs that improve the Drivelacutamab near-term value pipelin
Slide 5: 2022 highlights: Flawless execution of our strategic priorities
2022 highlights: Flawless execution of our strategic priorities Pipeline progress ANKET ® progress, Sanofi further AstraZeneca started PACIFIC-9 We continue to deliver investment with the addition of up Phase 3 trial of durvalumab plus lacutamab clinical development to 3 new programs, including in m
Slide 6: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Upcoming Milestone Sézary syndrome TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) Final data H2 2023 Mycosis Fungoides TELLOMAK Final data H2 2023 Lacutamab KIR3DL2 PTCL (combo with
Slide 7: Lacutamab | Preliminary efficacy results support further development
LACUTAMAB Lacutamab | Preliminary efficacy results support further development A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 treatment TELLOMAK Phase 2 Trial Cutaneous Cohort 1 – Sézary syndrome N ~ 60 Convincing preliminary Phase 2 data presented at ASH 2022 - Phase 1
Slide 8: Lacutamab | our development strategy
LACUTAMAB Lacutamab | our development strategy A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 treatment. TELLOMAK Cutaneous Phase 2 Trial T Cell lymphoma Sézary syndrome FDA Fast Track & EMA PRIME Cohort 1 (N~60) 3 cohorts (N~100) Orphan drug designation (US) Minimum of
Slide 9: Encouraging preliminary results in Sézary syndrome TELLOMAK Phase 2 trial
LACUTAMAB Encouraging preliminary results in Sézary syndrome TELLOMAK Phase 2 trial Lacutamab in patients with advanced Sézary syndrome: Results from an interim analysis from cohort 1 of the TELLOMAK Phase 2 trial. Patient baseline characteristics Preliminary efficacy results – Cohort 1 21.6% 35.1%
Slide 10: Encouraging preliminary results in KIR3DL2-expressing mycosis fungoides cohort
LACUTAMAB Encouraging preliminary results in KIR3DL2-expressing mycosis fungoides cohort of TELLOMAK Phase 2 trial Stage 1 results in MF patients with at least 2 prior line therapy Cohort 2 Cohort 3 KIR3DL2 expressors (n=21) KIR3DL2 non expressors (n=18) Skin Skin N % [95%CI] N % [95%CI] Global ORR
Slide 11: Monalizumab development in progress of Phases 2 and 3 trials
MONALIZUMAB Monalizumab development in progress of Phases 2 and 3 trials covering early stages of lung cancer Stage of disease NeoCOAST* Data presented: 2022 NeoCOAST-2* 30% major Patients with Stage II to IIIB NSCLC NSCLC pathological response Monalizumab + durvalumab + chemotherapy Stage I - III v
Slide 12: Strategic partnership with AstraZeneca
MONALIZUMAB Strategic partnership with AstraZeneca Monalizumab Milestone payment of $50 million received from AstraZeneca for the first patient treated in the Phase 3 trial, PACIFIC-9. Amounts received Total amount of the agreement: 1.275 billion US$ Potential amounts announced Milestone Initial pay
Slide 13: ANKET Proprietary NK cell engager platform
ANKET® Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46. ANKET® A versatile, fit-for-purpose technology that is creating an entirely new class Proprietary of tri- and tetra-specific molecules to induce synthetic Provides pro
Slide 14: ANKET NK cell engager molecules have the potential to strongly control tumor proliferation
ANKET® ANKET® NK cell engager molecules have the potential to strongly control tumor proliferation via the proliferation and activation of NK cells Innate Pharma differentiated MoA ASH 2022 updates Growing clinical pipeline Cell reports IPH6101 (CD123 ANKET) (Sanofi) IPH6101 (CD123) medicine Phase 1
Slide 15: Strategic partnership between Sanofi and Innate
ANKET® Strategic partnership between Sanofi and Innate Three molecules licensed to Sanofi plus two undisclosed targets under options IPH6101/SAR’579 IPH6401/SAR’514 IPH62 OPTION Ongoing CD123 BCMA B7-H3 2 undisclosed programs Phase 1 in AML Progression towards IND Research targets Upfront payments €
Slide 16: 2022 Financial highlights
2022 Financial highlights Revenue/other income from Operating expenses from continuing operations: Cash, cash equivalents and continuing operations: financial assets €57.7m (excluding 2022 Sanofi €25m) €74.1m LICENSING AND COLLABORATIONS 70% expenses related to R&D €49.6m €136.6m* as of December 31,
Slide 17: Upcoming catalysts
Upcoming catalysts Delivering across our strategic objectives • Monalizumab PACIFIC-9 | Phase 3 readout (AstraZeneca) • Monalizumab NeoCOAST-2 | Phase 2 readout (AstraZeneca) • IPH5201 (CD39) MATISSE | Phase2 readout (AstraZeneca) • IPH6101 ANKET® (CD123) | Phase 1 data (Sanofi) • IPH6401 ANKET® (BC
Slide 18: Key Takeaways: Strategic Priorities
Key Takeaways: Create value for patients and shareholders Strategic Priorities Robust pipeline and antibody engineering capabilities Advancing lacutamab Maximizing ANKET® platform Early R&D focus Continuing to explore ADC to drive value through later Track record of strategic partnerships stage Astr
Slide 19: Thank you
Thank you www.innate-pharma.com